Reportlinker Adds Pancreatic Cancer - Drug Pipeline Analysis and Market Forecasts to 2016

NEW YORK, May 27 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pancreatic Cancer - Drug Pipeline Analysis and Market Forecasts to 2016

http://www.reportlinker.com/p0202878/Pancreatic-Cancer---Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html

Pancreatic Cancer - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData's pharmaceutical and healthcare report offering, "Pancreatic Cancer – Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global pancreatic cancer market. This pharma report identifies the key trends shaping and driving the global pancreatic cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global pancreatic cancer sector.

The pancreatic cancer market is forecast to exhibit a negative CAGR of 4.1% between 2009 and 2016. This drop in revenues is mainly due to the estimated patent expiry of Gemzar and also for Xeloda. Although the new products that are currently in Phase III will enter the market soon, it will take some time for physicians to shift their present pattern of usage from Gemzar to the new products. While the genericization of Gemzar will influence the market revenues, no substantial improvement in the unmet need is expected. Newer entrants might exhibit promising results but they have yet to prove their efficacy. Overall, the pancreatic cancer market, which showed a healthy growth between 2001 and 2009, is predicted to witness a decline in revenues between 2009 and 2014.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope

The Scope of the report includes:

- Annualized global pancreatic cancer revenues data from 2001 to 2009, forecast forward for 7 years to 2016.

- Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.

- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.

- Analysis of the current and future market competition in the global pancreatic cancer market. The key market players covered are Pfizer, Wilex Inc and NewLink Genetics.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with pancreatic cancer.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global pancreatic cancer market.

- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global pancreatic cancer market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global pancreatic cancer market landscape? – Identify, understand and capitalize.

1 Table of contents 3

1.1 List of Tables5

1.2 List of Figures 5

2 Neutropenia Market: Market Characterization 6

2.1 Market Overview 6

2.2 Neutropenia Market Size 6

2.3 Neutropenia Market forecast and CAGR 7

2.4 Neutropenia Market Drivers 8

2.4.1 Steady Increase in the Prevalence Population 8

2.4.2 Increase in the Uptake of Biologics 9

2.4.3 Increase in the Prescription Population 9

2.4.4 Increase in Conditions Such as Cancer and Cardiovascular Events will Increase the Prevalence of drug induced Neutropenia 9

2.5 Neutropenia Market Restraints 9

2.5.1 Low Diagnosis Rate 9

2.5.2 Patent Expiries of Major Blockbuster Drugs Including Neupogen and Neulasta 10

2.5.3 Opening up of US market to biosimilars and generics 10

2.6 Opportunity and Unmet Need 10

2.6.1 Key Takeaway 11

3 Neutropenia Market: Competitive Assessment 12

3.1 Overview 12

3.2 Strategic Competitor Assessment 12

3.3 Product Profile for the Marketed Drugs for Neutropenia 13

3.3.1 Neulasta (Pegfilgrastim) 13

3.3.2 Neupogen 13

3.4 Product Profile for Off-Label Drugs for Neutropenia 14

3.4.1 Leukine 14

3.5 Key Takeaway 16

4 Neutropenia Market: Pipeline Assessment 17

4.1 Overview 17

4.2 Strategic Pipeline Assessment 17

4.2.1 Technology Trends Analytic Framework 17

4.3 Profile of the Promising Pipeline Molecules in Clinical Development 18

4.3.1 Voriconazole 18

4.3.2 Linezolid 19

4.3.3 Neugranin 19

4.3.4 Maxy-G34 20

4.4 Neutropenia – Clinical Pipeline by Mechanism of Action 20

4.5 Neutropenia Pipeline – Pipeline by Clinical Phases of Development 21

4.5.1 Neutropenia Market – Phase III Clinical Pipeline 22

4.5.2 Neutropenia Market – Phase II Clinical Pipeline 22

4.5.3 Neutropenia Market – Pre Clinical Pipeline 22

4.5.4 Neutropenia Market – Terminated Pipeline Molecules 23

4.5.5 Neutropenia Market – Approved Pipeline Molecules 23

4.6 Key takeaway 23

5 Neutropenia Market: Implications for Future Market Competition 24

6 Neutropenia Market: Future Players in Neutropenia Market 25

6.1 Introduction 25

6.2 Maxygen 25

6.2.1 Company Overview 25

6.2.2 Business Description 26

6.2.3 Hematology Disorder Portfolio 26

6.3 Pfizer 27

6.3.1 Company Overview 27

6.3.2 Financial Performance 28

6.3.3 Business Description 28

6.3.4 Hematology Disorder Portfolio 29

6.4 Teva Pharmaceutical Industries Limited 29

6.4.1 Company Overview 29

6.4.2 Financial Performance 30

6.4.3 Business Description 30

6.4.4 CoGenesys- The company acquired by Teva Pharmaceuticals 31

6.4.5 Blood Disorder Portfolio 31

7 Neutropenia Market: Appendix 33

7.1 Definitions 33

7.2 Acronyms 33

7.3 Research Methodology 33

7.3.1 Coverage 34

7.3.2 Secondary Research 34

7.3.3 Forecasting 35

7.3.4 Primary Research 37

7.3.5 Expert Panel Validation 38

7.4 Contact Us 38

7.5 Disclaimer 38

7.6 Sources 38

1.1 List of Tables

Table 1: Global Pancreatic Cancer Market Revenues, 2001-2009 5

Table 2: Global Pancreatic Cancer Market Forecasts, 2009-2016 6

Table 3: Gemcitabine Based Combinations Used for Treating Pancreatic Cancer, 2010 11

Table 4: Efficacy Results for Tarceva and Gemcitabine Versus Placebo in Patients with Pancreatic Cancer, 2010 13

Table 5: Major Marketed Products in the Pancreatic Cancer Market, 2010 14

Table 6: Pancreatic Cancer Therapeutics –Promising Drugs Under Clinical Development, 2010 17

Table 7: Mesupron Phase II Clinical Study Data, 2010 19

Table 8: Pancreatic Cancer Therapeutics – Phase III Clinical Pipeline, 2010 21

Table 9: Pancreatic Cancer Therapeutics – Phase II Clinical Pipeline, 2010 22

Table 10: Pancreatic Cancer Therapeutics – Phase I Clinical Pipeline, 2010 24

Table 11: Pancreatic Cancer Therapeutics – Preclinical Pipeline, 2010 25

Table 12: Pancreatic Cancer Therapeutics – Preclinical Pipeline, 2010 25

Table 13: List of Discontinued Drugs for Pancreatic Cancer, 2010 26

Table 14: Wilex: Pancreatic Cancer Pipeline, 2010 29

Table 15: Mesupron Phase II Clinical Study Data, 2010 30

Table 16: NewLink Genetics–Oncology Pipeline, 2010 30

Table 17: Pfizer – Oncology Pipeline, 2010 33

1.2 List of Figures

Figure 1: Global Pancreatic Cancer Market Revenues, 2001–2009 5

Figure 2: Global Pancreatic Cancer Market Forecast, 2009-2016 6

Figure 3: Opportunity and Unmet Need in the Pancreatic Cancer Market, 2010 8

Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Pancreatic Cancer, 2010 10

Figure 5: Technology Trends Analytic Framework of the Pancreatic Cancer Pipeline, 2010 16

Figure 6: Technology Trends Analytic Framework of Pancreatic Cancer Pipeline – Description, 2010 16

Figure 7: Pancreatic Cancer Pipeline by Mechanism of Action, 2010 20

Figure 8: Pancreatic Cancer Pipeline by Phase of Clinical Development, 2010 21

Figure 9: Implications for Future Market Competition in the Pancreatic Cancer Market, 2010 27

Figure 10: Pancreatic Cancer Therapeutics Market – Clinical Pipeline by Company, 2010 28

Figure 11: GlobalData Methodology, 2010 36

Figure 12: GlobalData Market Forecasting Model, 2010 39

Companies mentioned

Wilex Inc

NewLink Genetics

Pfizer

To order this report:

Drug and Medication Industry: Pancreatic Cancer - Drug Pipeline Analysis and Market Forecasts to 2016

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker